Cover Image
市場調查報告書

百日咳:開發中產品分析

Pertussis (Whooping Cough) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 192770
出版日期 內容資訊 英文 96 Pages
訂單完成後即時交付
價格
Back to Top
百日咳:開發中產品分析 Pertussis (Whooping Cough) - Pipeline Review, H1 2017
出版日期: 2017年06月27日 內容資訊: 英文 96 Pages
簡介

所謂百日咳是傳染性極強的呼吸疾病。是由百日咳菌這個細菌所引起。常見的症狀有鼻涕、鼻塞、噴嚏、充血、眼淚、乾咳等。治療方法包含抗生素等。

本報告提供百日咳治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

百日咳概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:各大學/研究機關

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

調查中的產品:各大學/研究機關

治療藥的開發企業

  • Beijing Minhai Biotechnology Co., Ltd
  • Beijing Tiantan Biological Products Co., Ltd.
  • Bharat Biotech International Limited
  • Biological E. Limited
  • Boryung Pharmaceutical Co., Ltd.
  • 第一三共
  • DBV Technologies S.A.
  • GlaxoSmithKline Plc
  • Green Cross Corporation
  • ILiAD Biotechnologies, LLC
  • Indian Immunologicals Limited
  • LG Life Science LTD.
  • NanoBio Corporation
  • Panacea Biotec Limited
  • Sanofi Pasteur SA
  • Serum Institute of India Limited
  • Sinovac Biotech Ltd.
  • Synthetic Biologics, Inc.
  • Zydus Cadila Healthcare Limited

治療藥的評估

  • 單獨療法的情況
  • 聯合治療的情況
  • 標的別
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9442IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pertussis (Whooping Cough) - Pipeline Review, H1 2017, provides an overview of the Pertussis (Whooping Cough) (Infectious Disease) pipeline landscape.

Pertussis, also known as whooping cough, is a highly contagious respiratory disease. It is caused by the bacterium Bordetella pertussis. Symptoms include runny nose, nasal congestion, sneezing, red, watery eyes and dry cough. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pertussis (Whooping Cough) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Pertussis (Whooping Cough) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pertussis (Whooping Cough) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Pertussis (Whooping Cough) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 8, 5, 6, 1, 8 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1 and 3 molecules, respectively.

Pertussis (Whooping Cough) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pertussis (Whooping Cough) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Pertussis (Whooping Cough) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pertussis (Whooping Cough) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pertussis (Whooping Cough) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pertussis (Whooping Cough) (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pertussis (Whooping Cough) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pertussis (Whooping Cough) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Pertussis (Whooping Cough) - Overview
    • Pertussis (Whooping Cough) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Pertussis (Whooping Cough) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Pertussis (Whooping Cough) - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co Ltd
    • Bharat Biotech International Ltd
    • Biological E Ltd
    • Boryung Pharmaceutical Co Ltd
    • Daiichi Sankyo Company Ltd
    • DBV Technologies SA
    • GlaxoSmithKline Plc
    • Green Cross Corp
    • Indian Immunologicals Ltd
    • Kaketsuken KK
    • LG Chem, Ltd.
    • NanoBio Corp
    • Sanofi
    • Sanofi Pasteur SA
    • Serum Institute of India Ltd
    • Shantha Biotechnics Pvt Ltd
    • Synthetic Biologics Inc
    • Zydus Cadila Healthcare Ltd
  • Pertussis (Whooping Cough) - Drug Profiles
    • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (wholl cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine 1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + pertussis (whole-cell) + tetanus) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis [serotypes Mahoney + MEF-1 + Saukett] + haemophilus influenza [serotype B]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis (acellular) + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (diphtheria + tetanus + pertussis (acellular)) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (hepatitis B + pertussis) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BK-1310 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bladder cancer + pertussis + tuberculosis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BVN-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DTaP-IPV-HB-PRPT - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GC-3111A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KD-370 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LBVD - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pertussis (acellular) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pertussis (acellular) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pertussis (whole cell) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pertussis [strain BPZE1] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pertussis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pertussis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SYN-005 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VN-0105 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Pertussis (Whooping Cough) - Dormant Projects
  • Pertussis (Whooping Cough) - Discontinued Products
  • Pertussis (Whooping Cough) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 19, 2017: Synthetic Biologics Reports Preclinical Data Demonstrating SYN-005 Provides Protection from Pertussis in Neonatal Animal Study
      • Mar 30, 2017: DBV Technologies, BioNet-Asia and Geneva University Hospitals Announce Phase I Trial Results of Viaskin rPT in Pertussis Booster Vaccination
      • Dec 13, 2016: Synthetic Biologics Announces Granting of U.S. Composition of Matter Patent for SYN-005, Designed for the Treatment and Prevention of Pertussis (Whooping Cough)
      • Nov 30, 2016: GENTICEL successfully completes determining milestone in partnership with Serum Institute regarding use of GTL003 in multivalent vaccines
      • Nov 17, 2016: DBV Technologies, BioNet-Asia and Geneva University Hospitals Complete Dosing in First Cohort of Phase I Study of Viaskin rPT for Booster Vaccination Against Pertussis
      • Sep 06, 2016: DBV Technologies, BioNet-Asia and the Geneva University Hospitals Initiate Phase I Study of Viaskin rPT for Pertussis Booster Vaccination
      • Jul 27, 2016: Nanobio to Present Intranasal Pertussis Vaccine Data at the Mucosal Immunology Course & Symposium Meeting
      • Oct 21, 2015: Grant Awarded to Synthetic Biologics' Academic Collaborator to Fund Further Evaluation of Monoclonal Antibody for the Prevention of Whooping Cough
      • Jun 10, 2015: Key Scientific Data Demonstrating that Epicutaneous Administration May Reactivate Protective Immunity against Pertussis in an experimental model published in Vaccine
      • Apr 27, 2015: Posters at ECCMID 2015 Highlight Preclinical Data from Synthetic Biologics' Novel SYN-005 Monoclonal Antibody Combination for the Treatment and Prophylaxis of Whooping Cough (Pertussis)
      • Mar 02, 2015: Synthetic Biologics Announces Two Poster Presentations of Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at ECCMID 2015
      • Nov 24, 2014: CanSinotech submitted CTA of "Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed" to CFDA
      • Sep 12, 2014: Synthetic Biologics Receives Orphan Drug Designation for SYN-005 Treatment for Whooping Cough (Pertussis)
      • Sep 08, 2014: Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program
      • Aug 19, 2014: Synthetic Biologics Announces Late-Breaking Poster Presentation for C. difficile Program at 54th ICAAC
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Pertussis (Whooping Cough), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Pertussis (Whooping Cough) - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
  • Pertussis (Whooping Cough) - Pipeline by Bharat Biotech International Ltd, H1 2017
  • Pertussis (Whooping Cough) - Pipeline by Biological E Ltd, H1 2017
  • Pertussis (Whooping Cough) - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2017
  • Pertussis (Whooping Cough) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Pertussis (Whooping Cough) - Pipeline by DBV Technologies SA, H1 2017
  • Pertussis (Whooping Cough) - Pipeline by GlaxoSmithKline Plc, H1 2017
  • Pertussis (Whooping Cough) - Pipeline by Green Cross Corp, H1 2017
  • Pertussis (Whooping Cough) - Pipeline by Indian Immunologicals Ltd, H1 2017
  • Pertussis (Whooping Cough) - Pipeline by Kaketsuken KK, H1 2017
  • Pertussis (Whooping Cough) - Pipeline by LG Chem, Ltd., H1 2017
  • Pertussis (Whooping Cough) - Pipeline by NanoBio Corp, H1 2017
  • Pertussis (Whooping Cough) - Pipeline by Sanofi, H1 2017
  • Pertussis (Whooping Cough) - Pipeline by Sanofi Pasteur SA, H1 2017
  • Pertussis (Whooping Cough) - Pipeline by Serum Institute of India Ltd, H1 2017
  • Pertussis (Whooping Cough) - Pipeline by Shantha Biotechnics Pvt Ltd, H1 2017
  • Pertussis (Whooping Cough) - Pipeline by Synthetic Biologics Inc, H1 2017
  • Pertussis (Whooping Cough) - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
  • Pertussis (Whooping Cough) - Dormant Projects, H1 2017
  • Pertussis (Whooping Cough) - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Pertussis (Whooping Cough) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Pertussis (Whooping Cough), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top